Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA in IgAN at ASN 2026 and Published in NEJM
Covered in this story
Call it yourself
No calls on $VERA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Vera Therapeutics Inc Class a →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.